Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
December 13, 2021 18:15 ET
|
Agios Pharmaceuticals, Inc.
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients – –...
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
December 13, 2021 10:30 ET
|
Agios Pharmaceuticals, Inc.
– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated – – Agios to Host Investor Webcast on Dec. 14,...
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
December 13, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients – – Safety Profile Consistent with Previously Reported Clinical Data – – Agios Announces Initiation of...
Agios Appoints Richa Poddar as Chief Commercial Officer
November 15, 2021 16:01 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
November 04, 2021 09:00 ET
|
Agios Pharmaceuticals, Inc.
– Extension Data for Mitapivat in PK Deficiency and Thalassemia Demonstrate Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis – – New Data from Two Investigator...
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
November 03, 2021 07:11 ET
|
Agios Pharmaceuticals, Inc.
– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 – – Initiated ENERGIZE and ENERGIZE-T Phase 3 Studies...
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
October 21, 2021 16:01 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios To Present at September Investor Conferences
August 30, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for...
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
August 17, 2021 16:01 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for...
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
July 29, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU – – Presented Data from ACTIVATE and ACTIVATE-T Phase 3 Studies...